Nearly 1· 5 years into the global COVID-19 pandemic, immense progress has been made
against SARS-CoV-2 in health care, most prominently in vaccine development. However …

Even in the aftermath of global anti-SARS-CoV-2 vaccination campaigns, safe and effective
treatments to inhibit inflammation and reduce mortality continue to be needed for the …

The COVID-19 pandemic, caused by the spread of severe acute respiratory syndrome
coronavirus 2, has resulted in more than 1· 8 million deaths worldwide as of Jan 7, 2021, a …

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome corona virus 2 (SARS-CoV-2), continues to spread globally despite …

Therapeutic approaches to mitigate the severe acute lung injury associated with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have rapidly entered …

To date, the SARS-CoV-2 virus and COVID-19 has killed more than 4 million individuals
worldwide. Morbidity and mortality arise from direct viral-induced injury to multiple organ …

As we approach the end of the second year of the COVID-19 pandemic, of the many
challenges facing immunologists and vaccinologists, one of the toughest has been the …

As of May, 2022, the SARS-CoV-2 virus has caused 521 million COVID-19 cases and at
least 6 million deaths, worldwide. 1 Although the COVID-19 pandemic has led to …

COVID-19 has caused hundreds of thousands of intensive care unit (ICU) admissions
worldwide, and this number continues to increase rapidly as of mid-May, 2021, particularly …

The Lancet Respiratory Medicine, Thomas L Holland and colleagues present results of the
ACTIV-3 trial comparing intravenous tixagevimab− cilgavimab with placebo for patients …